

UNITED STATES DECARMENT OF COMMERCE Patent and Trademark Office

بريات

## NOTICE OF ALLOWANCE AND ISSUE FEE DUE

ыыўэли609 т

ROBERT C NABINGER FISH & RICHARDSON 225 FRANKLIN STREET BOSTON MA 02110-2804

APPLICATION NO.	FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT	*,	DATE MAILED
08/963,227	11/03/97	กยย์	HARRISON, R	1617	06/09/99
First Named Applicant AHLUWALIA	<b>\</b> ;	35 U	SC 154(b) term ext. =	0 Days	•

TITLE OF INMIDITION OF HAIR GROWTH

			- Assert		<u> </u>			
ATTY'S DO	CKET NO.	CLASS-SUBCLASS	BATCH NO.	APF	PLN. TYPE	SMALL ENTITY	FEE DUE	DATE DUE
1 0	0216/283	0002 5116	80.000	U24	UTILIT	y NO	\$1210.00	09/09/99

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED.

THE ISSUE FEE MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. <u>THIS STATUTORY PERIOD CANNOT BE EXTENDED.</u>

#### HOW TO RESPOND TO THIS NOTICE:

- I. Review the SMALL ENTITY status shown above.
  If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:
  - A. If the status is changed, pay twice the amount of the FEE DUE shown above and notify the Patent and Trademark Office of the change in status, or
  - B. If the status is the same, pay the FEE DUE shown above.

If the SMALL ENTITY is shown as NO: \( \)

- A. Pay FEE DUE shown above, or
- B. File verified statement of Small Entity Status before, or with, payment of 1/2 the FEE DUE shown above.
- II. Part B-Issue Fee Transmittal should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B Issue Fee Transmittal should be completed and returned. If you are charging the ISSUE FEE to your deposit account, section "4b" of Part B-Issue Fee Transmittal should be completed and an extra copy of the form should be submitted.
- III. All communications regarding this application must give application number and batch number.

  Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

iMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

# Notice of Allowability

Application No. 08/963,227

Applicant(s)

Ahluwalia et al

Examiner

Robert H. Harrison

Group Art Unit 1617



All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance and Issue Fee Due or other appropriate communication will be mailed in due course.
∑ This communication is responsive to <u>applicants' amendment filed as of April 19, 1999</u> .
☐ The allowed claim(s) is/are 1-26 and 28-89
$\mathbf{X}$ The drawings filed on $2 1 1 1 1 9 9$ are acceptable.
☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been
☐ received.
received in Application No. (Series Code/Serial Number)
received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
*Certified copies not received:
☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
A SHORTENED STATUTORY PERIOD FOR RESPONSE to comply with the requirements noted below is set to EXPIRE THREE MONTHS FROM THE "DATE MAILED" of this Office action. Failure to timely comply will result in ABANDONMENT of this application. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).
□ Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL APPLICATION, PTO-152, which discloses that the oath or declaration is deficient. A SUBSTITUTE OATH OR DECLARATION IS REQUIRED.
Applicant MUST submit NEW FORMAL DRAWINGS
☐ because the originally filed drawings were declared by applicant to be informal.
including changes required by the Notice of Draftsperson's Patent Drawing Review, PTO-948, attached hereto or to Paper No
including changes required by the proposed drawing correction filed on, which has been approved by the examiner.
including changes required by the attached Examiner's Amendment/Comment.
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.
☐ Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.
Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included.
Attachment(s)
Notice of References Cited, PTO-892
Information Disclosure Statement(s), PTO-1449, Paper No(s).
☐ Notice of Draftsperson's Patent Drawing Review, PTO-948
Notice of Informal Patent Application, PTO-152
Examiner's Comment Regarding Requirement for Deposit of Biological Material
X Examiner's Statement of Reasons for Allowance

Application/Control Number: 08/963,227 Page 2

Art Unit: 1617

### **EXAMINER'S AMENDMENT**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Robert C. Nabinger on June 3, 1999.

2. The application has been amended as follows:

## THE CLAIMS

- In claim 74, line 8 (counting only lines of text) delete "phenyl-ethylene derivatives" and insert therefore --tamoxifen; rafoxidine--.
- 3. The following is an examiner's statement of reasons for allowance:

Claim 74 and all claims dependent thereon are free of the prior art since U.S. Patent 5,189,212 discloses topical application of phenyl-ethylene derivatives such as tamoxifen acids are useful to treat excessive hair growth including hursutism but unsubstituted tamoxifen is not disclosed. The remaining claims are allowed for the reasons advanced by applicants since the cimetidine is not topically applied. '375 to Duranton is cited of interest since it is disclosed sulphotransferase

Application/Control Number: 08/963,227 Page 3

Art Unit: 1617

inhibitor used to inhibit hair growth when topically applied. However, this reference is not available as prior art.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert H. Harrison whose telephone number is (703) 308-2422. The examiner can normally be reached on Monday-Thursday from 7:30 a.m. to 6:00 p.m. EST.

The fax phone number for most official papers or communications to <u>Technology Center</u>

1600/2900 - Group 1610 - Art Unit 1617 is (703) 308-4556. Such papers or communications

must conform with the notice published in the Official Gazette, 1096 OG 30; November 15, 1989.

The fax phone number for informal or unofficial communications (i.e., proposed claim(s) or amendment(s), and/or an outline of an upcoming interview) is (703) 308-7924. The support staff is not responsible for forwarding these communications to the examiner.

Art Unit: 1617

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group 1610 receptionist whose telephone number is (703) 308-1234.

Robert H. Harrison
Primary Examiner
Tech. Center 1600/2900
Group 1610
Art Unit 1617

RHHarrison/rhh June 6, 1999